Tracking inflammation response in triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial studies how a blood inflammation marker (CRP) changes after starting immunotherapy plus chemotherapy in people with triple-negative breast cancer. Results may help doctors predict who benefits from treatment and when.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- You have invasive breast cancer that is early, advanced, or metastatic
- Your breast cancer tests negative for ER, PR, and HER2 (triple-negative)
- If your cancer is advanced/metastatic, it must be PD-L1 positive (as defined by the trial)
- You must be planning to start immunotherapy (ICI) with chemotherapy for this study and be able to sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a blood test can track how well chemotherapy is working in people with early-stage triple-negative breast cancer. You would provide blood samples before and during treatment, and the results may help your doctor understand your response better.
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial looks at how a blood inflammation marker (CRP) changes when people with metastatic gynecologic cancers receive immunotherapy, sometimes together with palliative chemotherapy. The goal is to see patterns that may help doctors better understand and manage treatment responses to immunotherapy.
This study helps doctors predict which patients will respond best to immunochemotherapy (a combination of immune-boosting and chemotherapy drugs) for early-stage triple-negative breast cancer. By understanding your tumor better before treatment, doctors may be able to personalize your care plan.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.